Australia
Bionomics Ltd, a clinical-stage biopharmaceutical company, traded on Nasdaq as BNOX and ASX as BNO, focuses on developing novel drug candidates targeting patients with anxiety and stressor-related CNS disorders. The company's lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, is being advanced for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder.
Additionally, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.
Founded in 1999 and headquartered in Australia, Bionomics recently secured a $5.00M Post-IPO Equity investment on 21 November 2022 from Korify Capital. The company strives to address high unmet medical needs in the biotechnology industry, aiming to have a transformative impact on patients' lives.
For more information about Bionomics, its pipeline, and collaboration opportunities, visit the company's website at www.bionomics.com.au.
